FDA and digital health advisory committee (DHAC) members suggested a slew of generative artificial intelligence policies at their inaugural meeting this week, including new guidance for manufacturers on crafting post-market monitoring plans and calculating AI hallucinations along with requirements around stress testing AI, reporting AI errors to a centralized database and AI output watermarks. During the DHAC’s meeting on Wednesday and Thursday (Nov. 20-21), FDA officials also articulated unique challenges regulators see with generative AI-enabled devices, such as manufacturers struggling...